Attovia Therapeutics (NASDAQ:ATTO) Price Target Raised to $34.00

Attovia Therapeutics (NASDAQ:ATTO) had its target price lifted by Citigroup from $30.00 to $34.00 in a research note published on Tuesday,Benzinga reports. Citigroup currently has a buy rating on the stock.

A number of other brokerages have also weighed in on ATTO. Wall Street Zen raised shares of Attovia Therapeutics to a “sell” rating in a report on Saturday, September 19th. Lifesci Capital assumed coverage on Attovia Therapeutics in a research report on Monday, August 31st. They issued an “outperform” rating and a $45.00 target price on the stock. Leerink Partners started coverage on Attovia Therapeutics in a research note on Monday, August 31st. They issued an “outperform” rating and a $52.00 target price for the company. Royal Bank Of Canada began coverage on Attovia Therapeutics in a research report on Monday, August 31st. They set an “outperform” rating and a $45.00 price target for the company. Finally, Zacks Research upgraded Attovia Therapeutics to a “hold” rating in a research note on Friday, September 4th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.20.

Attovia Therapeutics Stock Down 5.5%

ATTO stock opened at $15.81 on Tuesday. Attovia Therapeutics has a 52 week low of $12.94 and a 52 week high of $28.00. The stock has a 50 day moving average of $17.71.

Attovia Therapeutics (NASDAQ:ATTO) last issued its quarterly earnings results on Monday, November 9th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). The company’s revenue was down 100.0% compared to the same quarter last year. During the same quarter last year, the business posted ($3.44) EPS. As a group, equities research analysts forecast that Attovia Therapeutics will post -4.19 EPS for the current fiscal year.

About Attovia Therapeutics

Attovia Therapeutics is a clinical-stage biotechnology company developing medicines for inflammatory and immune-mediated diseases. Its research focuses on antibody-based therapies intended to address biological pathways involved in these conditions. The company’s programs are in development, and its work centers on discovering and advancing potential treatments rather than marketing established products. Attovia Therapeutics is listed on the Nasdaq under the symbol ATTO. Publicly available information about the company’s history, leadership and geographic operations is limited.